CCSG Supplement: University of Kentucky Markey Cancer Center Support Grant ECIA Supplement

Project Abstract Dr. Myint’s narrative outlines her significant contributions to promoting a culture of successful clinical research at the Markey Cancer Center (MCC). Trained in internal medicine and hematology/oncology, she has garnered numerous accolades during her fellowship, demonstrating a commitment to translation research. As an Assistant Professor, Dr. Myint’s involvement in NCI-funded clinical trials and leadership roles, such as co-chair of GU CCART and Director of the GU program, showcase her dedication to advancing MCC’s research mission. Her current research activities span six investigator-initiated trials (IITs) focusing on various aspects of genitourinary cancer, leveraging MCC resources. Notably, her phase I study on epidiolex in biochemically recurrent prostate cancer received CCSG pilot grant funding, presenting at national meetings and publishing in Cancers journal. Her expertise extends to NCI-funded cooperative group trials, where she excels in patient accrual, aligning with MCC’s commitment to broadening treatment options. Looking ahead, Dr, Myint envisions a multifaceted role under the CCITLA award. She aims to ensure a diverse clinical trials portfolio, collaborating with MCC’s Clinical Trials Feasibility Committee, and spearheading initiatives for a Phase I/II radiopharmaceutical program. Actively engaging with basic scientists and mentoring junior faculty aligns with her vision for a thriving research culture. Additionally, she plans to serve as the principal investigator for a variety of genitourinary oncology trials, further elevating MCC’s clinical research profile. Her ambitious plans include facilitating workshops, applying for NCI support, and opening NCI-backed trials. Dr. Myint’s mentorship and commitment to junior faculty development underscore her dedication to MCC’s future leadership. The CCITLA support will be pivotal, affording her protected time to drive these initiatives, thereby fortifying MCC’s position as a hub for innovative clinical research.